Genetic and pharmacologic targeting of the PTEN/PI3K/Akt/mTOR signaling pathway was used as a potential therapeutic strategy in the peripheral neuropathies Hereditary Neuropathy with Liability to Pressure Palsies (HNPP) and Charcot Marie Tooth disease type 1A (CMT1A). This evidence concerns the gene AKT1 and Charcot-Marie-Tooth disease type 1A.